Identification of US-pharmaceutical patents expiring between 2018 and 2022 and their effect on the Brazilian domestic market
Ontology highlight
ABSTRACT:
SUBMITTER: Paes T
PROVIDER: S-EPMC7538125 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
Similar Datasets
Project description:Used-car market monitoring was started in 2018, 03 January, when Federal Administrative Court in Leipzig (Germany) allowed cities and communes in Germany to impose bans for diesel cars in order to reduce the level of nitric oxide in the air. This decision can radically change used-car market in the EU, because Germany massive exports used cars to Eastern Europe. The database shows the influence of the Germany Court decision to the used-car market in Latvia, as part of the EU market. The database represents the used-car market monitoring in Latvia during 2018. In Latvia 20-22th. used-car are offered for sale each month. The database reflects the observation dynamics of 12 months. In the observations there are included main used-car characteristics such as price, first registration date, motor cubic capacity, motor type, gearbox type, mileage, color, producer (brand), model, body types, (following) technical inspection data, set (features) of cars and so on.
| S-EPMC6362865 | biostudies-other
Project description:The introduction of the exact nuclear Overhauser enhancement (eNOE) methodology to solution-state nuclear magnetic resonance (NMR) spectroscopy results in tighter distance restraints from NOEs than in convention analysis. These improved restraints allow for higher resolution in structure calculation and even the disentanglement of different conformations of macromolecules. While initial work primarily focused on technical development of the eNOE, structural studies aimed at the elucidation of spatial sampling in proteins and nucleic acids were published in parallel prior to 2018. The period of 2018-2022 saw a continued series of technical innovation, but also major applications addressing biological questions. Here, we review both aspects, covering topics from the implementation of non-uniform sampling of NOESY buildups, novel pulse sequences, adaption of the eNOE to solid-state NMR, advances in eNOE data analysis, and innovations in structural ensemble calculation, to applications to protein, RNA, and DNA structure elucidation.
| S-EPMC9596134 | biostudies-literature
Project description:BackgroundThe United States requires a patent linkage system in other countries as part of free trade agreements. However, introducing a patent linkage system could be a significant barrier to the timely approval of generic drugs. This study aimed to evaluate the perceived impact of the patent linkage system in South Korea held by domestic manufacturers and analyze variations in evaluating the system according to the characteristics of domestic manufacturers.MethodsIn 2020, we conducted a questionnaire survey of 39 domestic manufacturers. The survey consisted of perceptions of the system, factors affecting patent challenges, and the perceived impact of the system. A 5-point Likert scale was used to rate each item. Domestic manufacturers were categorized into three groups based on their experience of listing a patent and acquiring first generic exclusivity.ResultsMore than half of the manufacturers surveyed had experience of listing a patent. The patent linkage system could protect the involved patents. However, manufacturers perceived that they could successfully challenge the validity of the involved patents and then obtained market approval for generic drugs. Manufacturers responded that market size, expectations for succeeding in litigation, and expectations for manufacturing the drug were the most relevant factors when they initiated patent challenges. Manufacturers reported that the system, in particular the first generic exclusivity, enhanced the research and development capability of generic manufacturers, increased their domestic sales, and improved access to generic drugs.ConclusionsThe perceived impact of the patent linkage system was limited to the domestic market and generic drugs. In narrowing the impact to the effects on the domestic industry, the system had positive impacts of the system on generic manufacturers. The first generic drug exclusivity lies at the center of this positive perception. However, manufacturers perceived that the current system did not provide enough incentives for domestic manufacturers to be granted first generic drug exclusivity through patent challenges.
| S-EPMC8935685 | biostudies-literature
Project description:Pharmaceutical Co-crystals are not new, they have gained much attention since the last decade among scientists and pharmaceutical industry. Pharmaceutical co-crystals are multicomponent systems composed of two or more molecules and held together by non-covalent interactions. The development of pharmaceutical co-crystals, a new solid crystalline form, offer superior physico-chemical properties (such as melting point, stability, solubility, permeability, bioavailability, taste masking, etc.) without altering the pharmacological properties. Recently, with the upsurge in the growth of Pharmaceutical co-crystals, the major concern is over the regulatory status of co-crystals. With the new guidelines from United States Food and Drug Administration (USFDA) and European Medicines Agency (EMA), the status has become even more complicated due to significantly different opinions. This review highlights whether co-crystals fulfil the requirements for the grant of a patent or not and how cocrystals are going to affect the present scenario of pharmaceuticals.
| S-EPMC6156475 | biostudies-other
Project description:Brazilian stock markets underwent a period of remarkable exuberance between early 2016 and March 2020, only to crash with the global turmoil related to health worries and oil prices. The Ibovespa index tripled its market value between a low point in January 2016 and its maximum in January 2020-by March 12, half those gains had been erased. Narratives about a bubble in Brazilian stocks before the global crash and its subsequent burst are plentiful in specialized media. In this paper, we explore this narrative from within the framework of strict local martingale financial bubbles. A key result in this literature states some financial asset price displays a bubble only if it follows a strict local martingale under the equivalent risk-neutral measure. A diffusion process is a strict local martingale if its volatility increases faster than linearly as its level grows. We first apply a nonparametric method to estimate the volatility function of Ibovespa daily prices, then fit a stochastic volatility model whose parameter values can discriminate the underlying price process as either a true martingale or a strict local martingale. Our results are negative towards the presence of a strict local martingale bubble in the Ibovespa index. Strict local martingale bubbles are related to a positive relationship between returns and volatility which does not seem present in the data at hand. We also performed a comparative analysis of the patterns found for the Ibovespa with the S&P500 index, spot Brent oil and gold prices.
| S-EPMC7605144 | biostudies-literature
Project description:BackgroundDrug repurposing is a group of development strategies employed in order to overcome some of the hurdles innate to drug research and development. Drug repurposing includes drug repositioning, reformulation and combination.ObjectiveThis study aimed to identify the determinants of successful market access outcome for drug repurposing in the United States of America (USA) and in Europe.MethodsThe case studies of repurposing strategies were identified through a systematic review of the literature. Price information and reimbursement conditions for all the case studies were collected mainly through access of public datasources. A list of attributes that could be associated with market access outcome (price level and reimbursement conditions) was developed, discussed, and validated by an external expert group. Detailed information for all attributes was researched and collected for each case study. Bivariate regression models were conducted to identify factors associated with price change for all repurposing cases. A similar analysis was performed for reformulation and repositioning cases, in the USA and in Europe, separately. A significance level of 5% was used for all analyses.ResultsA total of 144 repurposing case studies were included in the statistical analysis for evaluation of mean price change. Combination cases (the combination of two or more individual drug components) were excluded from the statistical analysis due to the low number of cases retrieved. The main attributes associated with a significant price increase for overall repurposing cases were 'change in administration setting to hospital' (374%, p<0.0001), 'addressing unmet needs' (69%, p<0.05), 'reformulations belonging to Group 3'-that is, change in administration route (117%, p<0.001), and being a repurposed product with the 'same brand name' as the original product (65%, p<0.05).ConclusionWe found that the ability of the repurposed product to address unmet needs, a reformulation where the target product had a different administration route than the source product, and having a similar brand name for repurposed and original products, were variables that impacted a positive price change for repurposed drugs overall. Our research results also suggested that orphan designation could have a positive impact for repositioning in the USA, in particular. Although a change of administration from ambulatory to hospital setting seemed to be significantly correlated with a price increase for the target product, only one case was retrieved for this parameter; as such, it was not possible to infer a firm correlation between this parameter and a change in price.
| S-EPMC4865758 | biostudies-literature
Project description:BackgroundWhile there has been much discussion by policymakers and stakeholders about the effects of "secondary patents" on the pharmaceutical industry, there is no empirical evidence on their prevalence or determinants. Characterizing the landscape of secondary patents is important in light of recent court decisions in the U.S. that may make them more difficult to obtain, and for developing countries considering restrictions on secondary patents.Methodology/principal findingsWe read the claims of the 1304 Orange Book listed patents on all new molecular entities approved in the U.S. between 1988 and 2005, and coded the patents as including chemical compound claims (claims covering the active molecule itself) and/or one of several types of secondary claims. We distinguish between patents with any secondary claims, and those with only secondary claims and no chemical compound claims ("independent" secondary patents). We find that secondary claims are common in the pharmaceutical industry. We also show that independent secondary patents tend to be filed and issued later than chemical compound patents, and are also more likely to be filed after the drug is approved. When present, independent formulation patents add an average of 6.5 years of patent life (95% C.I.: 5.9 to 7.3 years), independent method of use patents add 7.4 years (95% C.I.: 6.4 to 8.4 years), and independent patents on polymorphs, isomers, prodrug, ester, and/or salt claims add 6.3 years (95% C.I.: 5.3 to 7.3 years). We also provide evidence that late-filed independent secondary patents are more common for higher sales drugs.Conclusions/significancePolicies and court decisions affecting secondary patenting are likely to have a significant impact on the pharmaceutical industry. Secondary patents provide substantial additional patent life in the pharmaceutical industry, at least nominally. Evidence that they are also more common for best-selling drugs is consistent with accounts of active "life cycle management" or "evergreening" of patent portfolios in the industry.
| S-EPMC3515607 | biostudies-literature
Project description:Brazilian subtropical shallow lakes 2018 Targeted loci environmental
| PRJNA1000994 | ENA
Project description:ObjectiveTo assess the patterns of antibiotic consumption and expenditure in Vietnam.DesignThis was a cross-sectional study.SettingThis study used data of antibiotic procurement that was publicly announced from 2018 to 2022 as a proxy for antibiotic consumption.ParticipantsThis study included winning bids from 390 procurement units in 63 provinces in Vietnam for 5 years with a total expenditure of US$ 12.8 billions that represented for approximately 20-30% of the national funds spend on medicines.InterventionsAntibiotics were classified by WHO AWaRe (Access, Watch and Reserve) classification.Outcome measuresThe primary outcomes were the proportions of antibiotic consumptions in number of defined daily doses (DDD) and expenditures.ResultsThere was a total of 2.54 million DDDs of systemic antibiotics, which accounted for 24.7% (US $3.16 billions) of total expenditure for medicines purchased by these public health facilities. The overall proportion of Access group antibiotics ranges from 40.9% to 53.8% of the total antibiotic consumption over 5 years.ConclusionThis analysis identifies an unmet target of at least 60% of the total antibiotic consumption being Access group antibiotics and an unreasonable share of expenditure for non-essential antibiotics in public hospitals in Vietnam.
| S-EPMC11331946 | biostudies-literature
Project description:ObjectivesThis study examines the length of time between when a patent application is filed in Canada for a new drug and when it is available for patients (time to market) and various components of that time. It also looks at whether various factors explain the time between patent application to New Drug Submission (NDS) and compares Canadian and American times. Drugs approved between 1 January 2014 and 31 December 2018 are examined.DesignDescriptive study.Data sourcesWebsites from Health Canada, Food and Drug Administration, Merck Index, United States Patent and Trademark Office, WHO and previously published articles.InterventionsNone.Primary and secondary outcomesThe primary outcomes are time to market, time from patent application to NDS (pre-NDS time), review time, time from approval to availability (postapproval time) and factors that may influence the pre-NDS time. The secondary outcome is a comparison of Canadian and American review times and times between patent application and approval.ResultsThere were 113 drugs available for analysis. The median time to market was 11.80 years (IQR 9.40-14.05). The component median times were pre-NDS 10 years (IQR 8.05-12.80), review time 0.96 years (IQR 0.75-1.15) and postapproval time 0.15 years (IQR 0.08-0.28). Less than 8% of the pre-NDS time was explained by the factors that were analysed in a multiple linear regression equation. There was no statistically significant difference between Canadian and American pre-NDS times.ConclusionOnce a drug reaches the market, companies have a median of 8.2 years before the patent expires and generics can reach the market. Most of the time between the filing of a patent application and when a drug is marketed is determined by decisions that are largely under the control of the company.
| S-EPMC8258566 | biostudies-literature